Related Experiment Videos
Current and future radiopharmaceuticals for brain imaging with single photon emission computed tomography
1Department of Radiology, University of Pennsylvania, Philadelphia 19104.
Seminars in Nuclear Medicine
|October 1, 1990
Summary
New radiopharmaceuticals enable advanced functional brain imaging. These agents measure cerebral blood flow and central nervous system receptor concentrations for better brain function evaluation.
Area of Science:
- Neuroimaging
- Radiopharmaceutical Chemistry
Background:
- Functional brain imaging is crucial for understanding neurological disorders.
- Recent advancements in radiopharmaceutical development have accelerated progress in this field.
Purpose of the Study:
- To review the development of radiopharmaceuticals for functional brain imaging.
- To highlight agents for measuring regional cerebral blood flow and central nervous system receptors.
Main Methods:
- Utilizing [123I]-iodoamphetamine and [99mTc]-HMPAO for cerebral blood flow measurement.
- Developing new 123I-labeled agents for dopamine, serotonin, muscarinic, and benzodiazepine receptors.
- Employing single photon emission computed tomography (SPECT) for brain imaging.
Main Results:
- Established methods for measuring regional cerebral blood flow using specific radiotracers.
- Development of novel radioligands targeting key neurotransmitter systems.
- Demonstrated potential of SPECT with these agents for assessing receptor concentrations.
Conclusions:
- Radiopharmaceuticals significantly enhance the capability of functional brain imaging.
- These tools offer valuable insights into brain function by quantifying blood flow and receptor availability.
- Further clinical trials are exploring new technetium-based agents for broader applications.